Falkson C I, Falkson H C
Department of Medical Oncology, University of Pretoria, South Africa.
Oncology. 1995 Sep-Oct;52(5):427-31. doi: 10.1159/000227502.
Tropisetron was studied for efficacy and safety in 164 patients who were refractory to other antiemetic agents. 5 mg tropisetron was given intravenously, followed by 5 mg by mouth per day for 4 days. Complete prevention of nausea and vomiting was documented in 42% of patients on day 1 of cycle 1. Delayed nausea and vomiting were prevented in 41% in the first cycle. The antiemetic control did not decrease with subsequent cycles. Side effects ascribed to tropisetron were mild.
对164名对其他止吐药无效的患者进行了托烷司琼的疗效和安全性研究。静脉注射5毫克托烷司琼，随后每天口服5毫克，持续4天。在第1周期第1天，42%的患者实现了恶心和呕吐的完全预防。在第一个周期中，41%的患者预防了迟发性恶心和呕吐。后续周期的止吐控制效果并未降低。托烷司琼引起的副作用较轻。
